Discover some of the latest licensing deals executed by Wake Forest Innovations. In this report, learn about the licensing of novel technologies: a cancer therapeutic, a graft for heart valve replacement and a delivery method for oral medications.
The Center for Technology Innovation & Commercialization of Wake Forest Innovations takes some of the best ideas for medical technologies from the brightest minds at Wake Forest Baptist Medical Center—a leading academic research institution—and accelerates these ideas into medical innovations ready for licensing to an industry partner.
We celebrate each licensing success as another step toward our mission of improving health through collaborative innovation. The following contracts recently executed by the Center represent our dedication to that goal:
Muscadine Grape Extract
A patent-pending, proprietary muscadine grape extract—owned by Piedmont Research & Development and investigated by Wake Forest Baptist researchers Patricia Gallagher, PhD, and Elisabeth Tallant, PhD—has the potential to treat established cancers, to prevent or reduce the formation of primary cancer and to prevent or reduce the formation of secondary metastases. The Center for Technology Innovation & Commercialization granted an exclusive commercial-use license with Piedmont Research & Development Corporation for the application of the muscadine extract to the prevention and treatment of cancer.
Modified Alginate Hydrogels
Modified alginate hydrogels, a patent-pending novel method for encapsulating dietary supplements, prescription drugs, probiotics and various oils, were developed by Emmanuel Opara, PhD, from the Wake Forest Institute for Regenerative Medicine and Mark Welker, PhD, of Wake Forest University to reduce discomfort and increase the bioavailability of oral therapeutics and supplements. The Center executed an exclusive option to a license of the modified alginate hydrogels with Response Scientific.
Interested in learning more about the wealth of expertise at Wake Forest Baptist Medical Center or about our other technologies available for licensing? View our technology portfolio or contact us by email at firstname.lastname@example.org or by calling +1.336.713.1111.